Effect of psoriasis activity and topical treatment on serum lipocalin-2 levels

Baran, Anna; Świderska, Magdalena; Myśliwiec, Hanna; Flisiak, Iwona

doi:10.1080/09546634.2016.1180340

Cited by 17 publications

(19 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased irisin levels were associated with major adverse CV events in patients with established coronary artery disease after percutaneous coronary intervention. 31 In a recent study, Baran et al 32 found that serum irisin levels were insignificantly increased in psoriatic patients when compared with healthy controls ( p = 0.38). They also observed a positive statistical relation with irisin and lipocalin-2 (LCN-2).…”

Section: Discussionmentioning

confidence: 94%

Serum irisin level, insulin resistance, and lipid profiles in patients with hidradenitis suppurativa: a case-control study

Özkur

Erdem

Altunay

et al. 2020

Anais Brasileiros de Dermatologia

View full text Add to dashboard Cite

Background Hidradenitis suppurativa is a chronic inflammatory skin disease of terminal follicular acroinfundibulum. Objectives This study aimed to evaluate serum irisin, plasma glucose, insulin, and lipid levels in hidradenitis suppurativa, and elucidate possible associations with disease activity, inflammatory, or metabolic parameters. Methods This case-control study included 37 patients (M/F: 9/28) and 37 sex-, age- and body mass index -matched healthy controls (M/F: 11/26). Demographic data, Hurley stage of disease, fasting glucose, insulin, total cholesterol, high density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, C-reactive protein levels, erythrocyte sedimentation rate, hematologic parameters, and serum irisin were assessed. Results The hidradenitis suppurativa group had significantly higher waist circumference than controls ( p < 0.001). Insulin resistance, defined as a homeostatic model assessment for insulin resistance value greater than 2.5, was observed in 45.9% of patients and 8.1% of controls ( p = 0.003), whereas metabolic syndrome was observed in 32.4% of patients and 5.4% of controls ( p < 0.001). Furthermore, plasma triglycerids, glucose, and insulin levels were significantly higher in the hidradenitis suppurativa ( p = 0.013, p = 0.001, and p = 0.004), respectively. Mean irisin level was insignificantly higher in the hidradenitis suppurativa group (37.4 ± 32.6) than in controls (26.2 ± 24.7, p = 0.217). Study limitation Physical activity and the exercise levels of participants were not documented. Conclusion This study indicates that hidradenitis suppurativa patients have higher serum irisin, fasting plasma glucose, insulin, and triglycerides levels than healthy controls. Thus, the authors suggest that hidradenitis suppurativa patients should be evaluated for insulin resistance and metabolic syndrome, and monitored accordingly.

show abstract

Section: Discussionmentioning

confidence: 94%

Serum irisin level, insulin resistance, and lipid profiles in patients with hidradenitis suppurativa: a case-control study

Özkur

Erdem

Altunay

et al. 2020

Anais Brasileiros de Dermatologia

View full text Add to dashboard Cite

show abstract

“…Moreover, there are conflicting results regarding the correlation between serum LCN2 and PASI [12, 15]. However, serum LCN2 level may not be a reliable indicator in the efficacy of antipsoriatic treatment [7, 23].…”

Section: Discussionmentioning

confidence: 99%

“…It has been related to obesity, metabolic syndrome, and cardiovascular disease [6]. In addition, psoriasis has also been recognized as an independent risk factor for myocardial infarction, which may cause serious negative impact on the quality of life [7]. Psoriatic arthritis (PsA) is a chronic, inflammatory, and debilitating arthritis associated with psoriasis [8].…”

Section: Introductionmentioning

confidence: 99%

Association of Serum Lipocalin-2 Concentrations with Psoriasis and Psoriatic Arthritis: An Updated Meta-Analysis

2019

View full text Add to dashboard Cite

Objectives. The purpose of this study was to explore the association of serum lipocalin-2 concentrations with psoriasis and psoriatic arthritis (PsA). Methods. A systematic search of studies on the association of serum lipocalin-2 concentrations with psoriasis/PsA was conducted in PubMed, Web of Science, Elsevier ScienceDirect, and Cochrane Library. Eventually, 8 eligible studies were included. The strength of association between serum lipocalin-2 concentrations and psoriasis/PsA was assessed by pooled standard mean difference (SMD) with its 95% confidence intervals (CIs). Results. A total of 8 case-control studies, consisting of 349 psoriasis/PsA patients and 258 controls, were included in the meta-analysis. This meta-analysis showed significant association between serum lipocalin-2 concentrations and psoriasis/PsA in overall population (SMD: 0.757, 95%CI=0.588‐0.926, and PH=0.114; PH is the P value for the heterogeneity test). Similar results were found in subgroup analysis by ethnicity. Conclusions. Serum lipocalin-2 concentrations are higher in psoriasis/PsA patients than controls. However, more large-scale studies are warranted to explore the association between serum lipocalin-2 and the pathogenetic mechanisms of psoriasis/PsA.

show abstract

“…Baran et al [69] reported that serum lipocalin-2 levels were much higher in psoriatic patients than in controls, although they were not significantly related to the inflammation markers BMI or PASI. They concluded by saying that lipocalin-2 may be a good predictor of psoriasis and cardiovascular risk, but not a reliable indicator of inflammation, severity of psoriasis, or antipsoriatic treatment outcome.…”

Section: Association Between Some Obesity Biomarkers and Psoriasismentioning

confidence: 99%

Biomarkers of Inflammation in Obesity-Psoriatic Patients

Rodríguez-Cerdeira

Cordeiro-Rodríguez

Carnero-Gregorio

et al. 2019

Mediators of Inflammation

View full text Add to dashboard Cite

Psoriasis is a common chronic inflammatory multisystemic disease with a complex pathogenesis consisting of genetic, immunological, and environmental components. It is associated with a number of comorbidities, including diabetes, metabolic syndrome, obesity, and myocardial infarction. In addition, the severity of psoriasis seems to be related to the severity of obesity. Patients with higher levels of obesity show poorer response to systemic treatments of psoriasis. Several studies have demonstrated that white adipose tissue is a crucial site of the formation of proinflammatory adipokines such as leptin, adiponectin, and resistin and classical cytokines such as interleukin- (IL-) 6 and tumour necrosis factor-α. In psoriasis, due to the proliferation of Th1, Th17, and Th22 cells, IL-22, among others, is produced in addition to the abovementioned cytokines. With respect to leptin and resistin, both of these adipokines are present in high levels in obese persons with psoriasis. Further, the plasma levels of leptin and resistin are related to the severity of psoriasis. These results strongly suggest that obesity, through proinflammatory pathways, is a predisposing factor to the development of psoriasis and that obesity aggravates existing psoriasis. Different inflammatory biomarkers link psoriasis and obesity. In this paper, the most important ones are described.

show abstract

Effect of psoriasis activity and topical treatment on serum lipocalin-2 levels

Abstract: Lipocalin-2 might be a marker of psoriasis and convey cardiovascular or metabolic risk in psoriatic patients, but may not be a reliable indicator of inflammation, severity of psoriasis nor efficacy of antipsoriatic treatment.

Cited by 17 publications

References 20 publications

Serum irisin level, insulin resistance, and lipid profiles in patients with hidradenitis suppurativa: a case-control study

Serum irisin level, insulin resistance, and lipid profiles in patients with hidradenitis suppurativa: a case-control study

Association of Serum Lipocalin-2 Concentrations with Psoriasis and Psoriatic Arthritis: An Updated Meta-Analysis

Biomarkers of Inflammation in Obesity-Psoriatic Patients

Contact Info

Product

Resources

About